LIVN:NASDAQLivaNova PLC Analysis

LivaNova (LIVN) is trading around $65, just above its 20‑day (≈63.3) and 50‑day (≈64.8) simple moving averages, with a neutral RSI (≈55) and a bullish MACD histogram (+0.28) that signals short‑term momentum. The stock sits on a solid support near $60.35 and faces resistance around $66.72, while its beta (~1.2) and 30‑day volatility (~36%) suggest higher than average market risk. Fundamentally, the forward P/E of 14.2 is well below the industry average of 26.2, and the DCF‑derived fair value of $347 implies a potential upside of over 22%. Recent FDA pre‑market approval for the aura6000 system adds a clear growth catalyst, complementing a 12% revenue growth rate and strong free cash flow generation. Despite a negative trailing profit margin, the company projects a positive forward EPS and maintains a healthy cash‑to‑debt profile, supporting its undervalued status.
Overall, the combination of technical bullishness, a sizable valuation gap, and a new product approval positions LIVN as an attractive buy in the near term, while medium‑ to long‑term investors should monitor margin improvement and execution of the neuromodulation pipeline.